Page last updated: 2024-10-23

aspirin and Non-alcoholic Fatty Liver Disease

aspirin has been researched along with Non-alcoholic Fatty Liver Disease in 15 studies

Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.

Non-alcoholic Fatty Liver Disease: Fatty liver finding without excessive ALCOHOL CONSUMPTION.

Research Excerpts

ExcerptRelevanceReference
"Many basic mechanistic studies found that aspirin inhibited multiple pathways involved in non-alcoholic fatty liver disease (NAFLD) development."7.80Association between aspirin use and the prevalence of nonalcoholic fatty liver disease: a cross-sectional study from the Third National Health and Nutrition Examination Survey. ( Bostick, RM; Jawairia, M; Mustacchia, P; Shahzad, G; Shen, H, 2014)
"Aspirin treatment reduced body weight gain, reversed glucose intolerance, and depressed hepatic lipid accumulation in female, but not in male mice."5.51Sex-associated preventive effects of low-dose aspirin on obesity and non-alcoholic fatty liver disease in mouse offspring with over-nutrition in utero. ( Drake, M; Hao, Y; Jendrusch, C; Liu, Z; Peng, H; Xie, L; Zhang, KK; Zhou, Y, 2019)
"Non-alcoholic fatty liver disease (NAFLD) is now a public health issue worldwide, but no drug has yet received approval."5.48Genistein Ameliorates Non-alcoholic Fatty Liver Disease by Targeting the Thromboxane A ( Chen, J; Chen, W; Li, H; Mao, J; Wang, M; Wang, W; Zhang, H, 2018)
"Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver injury; however its therapeutic strategy has not been established yet."5.37Nitro-aspirin is a potential therapy for non alcoholic fatty liver disease. ( Abdelrahman, AM; Farghaly, E; Gomaa, W; Ibrahim, M; Kelleni, M, 2011)
"Many basic mechanistic studies found that aspirin inhibited multiple pathways involved in non-alcoholic fatty liver disease (NAFLD) development."3.80Association between aspirin use and the prevalence of nonalcoholic fatty liver disease: a cross-sectional study from the Third National Health and Nutrition Examination Survey. ( Bostick, RM; Jawairia, M; Mustacchia, P; Shahzad, G; Shen, H, 2014)
"Nonalcoholic steatohepatitis is a common finding in patients with CVD."2.80PolyPill for Prevention of Cardiovascular Disease in an Urban Iranian Population with Special Focus on Nonalcoholic Steatohepatitis: A Pragmatic Randomized Controlled Trial within a Cohort (PolyIran - Liver) - Study Protocol. ( Hemming, K; Jafari, E; Khoshnia, M; Malekzadeh, R; Marshall, T; Merat, S; Nateghi, A; Poustchi, H; Radmard, AR; Shiravi Khuzani, A, 2015)
"Animals without steatosis (ie NAFLD) at week 16 were excluded from the data analysis."1.62The effect of acetylsalicylic acid and pentoxifylline in guinea pigs with non-alcoholic steatohepatitis. ( Andersen, M; Buelund, LE; Ipsen, DH; Latta, M; Lintrup, K; Lykkesfeldt, J; Skaarup, R; Skat-Rørdam, J; Svenningsen, M; Tveden-Nyborg, P, 2021)
"Aspirin treatment reduced body weight gain, reversed glucose intolerance, and depressed hepatic lipid accumulation in female, but not in male mice."1.51Sex-associated preventive effects of low-dose aspirin on obesity and non-alcoholic fatty liver disease in mouse offspring with over-nutrition in utero. ( Drake, M; Hao, Y; Jendrusch, C; Liu, Z; Peng, H; Xie, L; Zhang, KK; Zhou, Y, 2019)
"Non-alcoholic fatty liver disease (NAFLD) is now a public health issue worldwide, but no drug has yet received approval."1.48Genistein Ameliorates Non-alcoholic Fatty Liver Disease by Targeting the Thromboxane A ( Chen, J; Chen, W; Li, H; Mao, J; Wang, M; Wang, W; Zhang, H, 2018)
"The degree of liver fibrosis was determined using four validated fibrosis indices and a composite index."1.43Aspirin use is associated with lower indices of liver fibrosis among adults in the United States. ( Afdhal, N; Feldbrügge, L; Ghaziani, T; Jiang, ZG; Mukamal, KJ; Popov, Y; Robson, SC; Tapper, EB, 2016)
"Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver injury; however its therapeutic strategy has not been established yet."1.37Nitro-aspirin is a potential therapy for non alcoholic fatty liver disease. ( Abdelrahman, AM; Farghaly, E; Gomaa, W; Ibrahim, M; Kelleni, M, 2011)

Research

Studies (15)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's10 (66.67)24.3611
2020's5 (33.33)2.80

Authors

AuthorsStudies
Ramandi, A1
George, J1
Merat, S2
Jafari, E2
Sharafkhah, M1
Radmard, AR2
Nateghi Baygi, A1
Delavari, A1
Mohammadi, Z1
Poustchi, H2
Malekzadeh, R2
Severo, MD1
Han, YM1
Lee, YJ1
Jang, YN1
Kim, HM1
Seo, HS1
Jung, TW1
Jeong, JH1
Ipsen, DH1
Skat-Rørdam, J1
Svenningsen, M1
Andersen, M1
Latta, M1
Buelund, LE1
Lintrup, K1
Skaarup, R1
Lykkesfeldt, J1
Tveden-Nyborg, P1
Wang, W1
Chen, J1
Mao, J1
Li, H2
Wang, M1
Zhang, H1
Chen, W1
Zhou, Y1
Peng, H1
Liu, Z1
Zhang, KK1
Jendrusch, C1
Drake, M1
Hao, Y1
Xie, L1
Simon, TG2
Henson, J1
Osganian, S1
Masia, R1
Chan, AT1
Chung, RT1
Corey, KE2
Vilar-Gomez, E1
Chalasani, N1
Shen, H1
Shahzad, G1
Jawairia, M1
Bostick, RM1
Mustacchia, P1
Armstrong, MJ1
Rowe, IA1
Hemming, K1
Nateghi, A1
Shiravi Khuzani, A1
Khoshnia, M1
Marshall, T1
Jiang, ZG1
Feldbrügge, L1
Tapper, EB1
Popov, Y1
Ghaziani, T1
Afdhal, N1
Robson, SC1
Mukamal, KJ1
Ibrahim, M1
Farghaly, E1
Gomaa, W1
Kelleni, M1
Abdelrahman, AM1
Russo, MW1
Pierson, J1
Narang, T1
Montegudo, A1
Eskind, L1
Gulati, S1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Fixed-dose Combination Therapy (PolyPill) in Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians - Focus on Liver-Related Variables.[NCT01245608]Phase 32,400 participants (Actual)Interventional2011-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

2 trials available for aspirin and Non-alcoholic Fatty Liver Disease

ArticleYear
Polypill protects MAFLD patients from cardiovascular events and mortality: a prospective trial.
    Hepatology international, 2023, Volume: 17, Issue:4

    Topics: Aspirin; Cardiovascular Diseases; Drug Combinations; Humans; Non-alcoholic Fatty Liver Disease; Pros

2023
PolyPill for Prevention of Cardiovascular Disease in an Urban Iranian Population with Special Focus on Nonalcoholic Steatohepatitis: A Pragmatic Randomized Controlled Trial within a Cohort (PolyIran - Liver) - Study Protocol.
    Archives of Iranian medicine, 2015, Volume: 18, Issue:8

    Topics: Angiotensin II Type 1 Receptor Blockers; Aspirin; Atorvastatin; Cardiovascular Diseases; Diuretics;

2015

Other Studies

13 other studies available for aspirin and Non-alcoholic Fatty Liver Disease

ArticleYear
Daily Aspirin Use Associated With Reduced Risk for Fibrosis Progression in Patients With Nonalcoholic Fatty Liver Disease.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2020, Volume: 18, Issue:2

    Topics: Aspirin; Disease Progression; Fibrosis; Humans; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease

2020
Aspirin Improves Nonalcoholic Fatty Liver Disease and Atherosclerosis through Regulation of the PPAR
    BioMed research international, 2020, Volume: 2020

    Topics: AMP-Activated Protein Kinases; Animals; Aspirin; Atherosclerosis; Dyslipidemias; Hep G2 Cells; Human

2020
The effect of acetylsalicylic acid and pentoxifylline in guinea pigs with non-alcoholic steatohepatitis.
    Basic & clinical pharmacology & toxicology, 2021, Volume: 128, Issue:4

    Topics: Animals; Aspirin; Diet, High-Fat; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Reposit

2021
Genistein Ameliorates Non-alcoholic Fatty Liver Disease by Targeting the Thromboxane A
    Journal of agricultural and food chemistry, 2018, Jun-13, Volume: 66, Issue:23

    Topics: Animals; Aspirin; Cyclooxygenase Inhibitors; Diet, High-Fat; Disease Models, Animal; Disease Progres

2018
Sex-associated preventive effects of low-dose aspirin on obesity and non-alcoholic fatty liver disease in mouse offspring with over-nutrition in utero.
    Laboratory investigation; a journal of technical methods and pathology, 2019, Volume: 99, Issue:2

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Weight; Diet, High-Fat; Female; Gluc

2019
Daily Aspirin Use Associated With Reduced Risk For Fibrosis Progression In Patients With Nonalcoholic Fatty Liver Disease.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2019, Volume: 17, Issue:13

    Topics: Adult; Aged; Aspartate Aminotransferases; Aspirin; Cohort Studies; Disease Progression; Duration of

2019
Daily Aspirin Use Reduces Risk of Fibrosis Progression in Patients With Nonalcoholic Fatty Liver Disease, Providing New Uses for an Old Drug.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2019, Volume: 17, Issue:13

    Topics: Aspirin; Disease Progression; Humans; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease

2019
Reply.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2020, Volume: 18, Issue:2

    Topics: Aspirin; Disease Progression; Fibrosis; Humans; Non-alcoholic Fatty Liver Disease

2020
Association between aspirin use and the prevalence of nonalcoholic fatty liver disease: a cross-sectional study from the Third National Health and Nutrition Examination Survey.
    Alimentary pharmacology & therapeutics, 2014, Volume: 40, Issue:9

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cross-Sectional Studies; Female; Huma

2014
Editorial: would an aspirin a day keep NAFLD and its complications away?
    Alimentary pharmacology & therapeutics, 2015, Volume: 41, Issue:1

    Topics: Aspirin; Female; Humans; Male; Non-alcoholic Fatty Liver Disease; Nutrition Surveys

2015
Aspirin use is associated with lower indices of liver fibrosis among adults in the United States.
    Alimentary pharmacology & therapeutics, 2016, Volume: 43, Issue:6

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cross-Sectional Studies; Female; Hepatitis,

2016
Nitro-aspirin is a potential therapy for non alcoholic fatty liver disease.
    European journal of pharmacology, 2011, Jun-01, Volume: 659, Issue:2-3

    Topics: Alanine Transaminase; Animals; Aspirin; Cyclooxygenase 2; Fatty Liver; Gene Expression Regulation, E

2011
Coronary artery stents and antiplatelet therapy in patients with cirrhosis.
    Journal of clinical gastroenterology, 2012, Volume: 46, Issue:4

    Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Fatty Liver; Female; Follow-Up Studies; Gastroi

2012